Key Points
- CEO Martine Rothblatt sold 9,500 shares on March 23 at an average price of $527.01 for a total of $5,006,595, reducing her stake by 19% to 40,513 shares (worth ≈$21.35M).
- CFO James Edgemond also sold about 10,000 shares (~$5.27M) in March, meaning sizeable officer sales could pressure sentiment despite being disclosed as routine.
- Fundamentals and analyst sentiment remain constructive — United Therapeutics beat EPS ($7.70 vs. $6.78) while revenue slightly missed, several firms raised price targets, and consensus is a Moderate Buy with an average target near $549.91 as shares trade close to their 52‑week high.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.01, for a total value of $5,006,595.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company's stock, valued at approximately $21,350,756.13. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $541.60 on Thursday. The business's fifty day moving average is $493.58 and its 200 day moving average is $471.33. The firm has a market cap of $23.74 billion, a price-to-earnings ratio of 19.41, a PEG ratio of 1.92 and a beta of 0.84. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $549.50.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm's revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the company earned $6.19 EPS. Equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.
Trending Headlines about United Therapeutics
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Several brokerages have lifted price targets and reiterated buy/outperform views (examples cited include HC Wainwright, RBC, Cantor Fitzgerald and UBS), supporting upside expectations and helping sentiment. Analyst Coverage Summary
- Positive Sentiment: Wells Fargo published a bullish forecast for UTHR, calling for meaningful price appreciation and adding directional support to the tape. Wells Fargo Research
- Positive Sentiment: Recent quarterly results showed EPS outperformance versus consensus (EPS beat), underpinning the fundamental case even as revenue slightly missed; analysts’ upward revisions follow those results. Quarterly Results Summary
- Neutral Sentiment: Brokerage consensus remains a “Moderate Buy” — constructive but not unanimous; this keeps expectations elevated but measured. Analyst Consensus
- Neutral Sentiment: Institutional ownership is high and several funds reported increasing stakes in recent quarters, which can support liquidity and reduce volatility. Institutional Holdings
- Negative Sentiment: Insider selling: CEO Martine Rothblatt sold 9,500 shares (~$5.0M) and CFO James Edgemond sold 10,000 shares (~$5.27M) in March; large officer sales can pressure sentiment even if company says sales are routine. SEC filings: CEO sale CEO SEC Filing, CFO sale CFO SEC Filing
- Neutral Sentiment: Short-interest reports in recent feeds show data anomalies (zero reported shares / NaN changes) and are not providing a clear short-squeeze or bearish signal at this time. Short Interest Data
Institutional Trading of United Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Torren Management LLC bought a new stake in shares of United Therapeutics during the 4th quarter worth $26,000. Activest Wealth Management increased its stake in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC increased its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new stake in United Therapeutics during the fourth quarter valued at about $31,000. Hedge funds and other institutional investors own 94.08% of the company's stock.
Analysts Set New Price Targets
Several equities analysts recently commented on the stock. Jefferies Financial Group reaffirmed a "buy" rating on shares of United Therapeutics in a research note on Monday, March 2nd. Weiss Ratings reiterated a "buy (b)" rating on shares of United Therapeutics in a research note on Monday, December 29th. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. Cantor Fitzgerald upped their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a report on Thursday, March 12th. Finally, Wells Fargo & Company increased their price objective on United Therapeutics from $466.00 to $486.00 and gave the stock an "equal weight" rating in a research report on Monday. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $549.91.
Check Out Our Latest Stock Report on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
